

Andrew A Wagner

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4495034/andrew-a-wagner-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

3,588
citations

32
h-index

57
g-index

147
ext. papers

4,707
ext. citations

5.1
avg. IF

5.02
L-index

#	Paper	IF	Citations
127	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>New England Journal of Medicine</i> , 2015 , 373, 428-37	59.2	309
126	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 835-40 ^{2.2}	2.2	297
125	Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. <i>European Urology</i> , 2015 , 68, 408-15	10.2	190
124	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171
123	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 478-487	40	148
122	Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 871-9	12.9	140
121	Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2013 , 26, 289-94	9.8	119
120	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. <i>Cancer</i> , 2012 , 118, 5894-902	6.4	114
119	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017 , 123, 3285-3290	6.4	106
118	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016 , 195, 313-20	2.5	93
117	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1266-1276	27.4	91
116	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2184-93	6.1	84
115	Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. <i>Cancer Research</i> , 2010 , 70, 639-45	10.1	80
114	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 2874-84	12.9	75
113	A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. <i>Clinical Cancer Research</i> , 2013 , 19, 6020-9	12.9	62
112	A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. <i>European Journal of Cancer</i> , 2017 , 76, 144-151	7.5	60
111	A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 1044-51	12.9	54

110	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. <i>Nature Communications</i> , 2016 , 7, 12609	17.4	53
109	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017 , 72, 448-454	10.2	49
108	Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. <i>American Journal of Roentgenology</i> , 2014 , 202, 252-8	5.4	49
107	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
106	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. <i>Clinical Therapeutics</i> , 2016 , 38, 778-93	3.5	45
105	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. <i>Oncotarget</i> , 2016 , 7, 16581-92	3.3	44
104	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019 , 37, 923-931 ^{2,2}	3.2	42
103	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1693-1701	2.2	40
102	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. <i>Journal of Urology</i> , 2016 , 196, 1356-1362	2.5	40
101	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015 , 68, 1083-8 ²	10.2	39
100	CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1346-53	6.1	39
99	A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>BJU International</i> , 2020 , 126, 265-272	5.6	37
98	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. <i>BJU International</i> , 2019 , 123, 42-50	5.6	33
97	Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2017 , 197, 1427-1436	2.5	32
96	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020 , 38, 831-843	4.3	32
95	Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. <i>Oral Oncology</i> , 2015 , 51, 1026-1033	4.4	30
94	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 364-372	6.2	29
93	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1549-1557	2.2	26

92	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 7287-7293	13.9	25
91	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019 , 32, 977-987	9.8	25
90	Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. <i>Journal of Urology</i> , 2015 , 194, 903-9	2.5	24
89	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015 , 21, 3178-86	12.9	23
88	Robotic Surgery of the Kidney, Bladder, and Prostate. <i>Surgical Clinics of North America</i> , 2016 , 96, 615-36	4	23
87	Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. <i>American Journal of Roentgenology</i> , 2016 , 206, 544-53	5.4	23
86	YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. <i>Gynecologic Oncology</i> , 2017 , 145, 531-535	4.9	22
85	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018 , 74, 211-217	10.2	22
84	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020 , 203, 727-733	3.5	20
83	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. <i>Modern Pathology</i> , 2019 , 32, 1158-1167	9.8	19
82	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016 , 61, 94-101	7.5	19
81	Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017 , 197, 109-114	2.5	18
80	Use of delayed intervention for small renal masses initially managed with active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 18-25	2.8	18
79	Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. <i>World Journal of Urology</i> , 2016 , 34, 1651-1656	4	17
78	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. <i>Urology</i> , 2016 , 91, 143-9	1.6	17
77	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
76	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11502-11502	2.2	14
75	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020 , 6, e203187	13.4	14

74	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
73	Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>BJU International</i> , 2017 , 120, 695-701	5.6	12
72	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 438-445	6.2	12
71	Collaborating with our adult colleagues: A case series of robotic surgery for suspicious and cancerous lesions in children and young adults performed in a free-standing children's hospital. <i>Journal of Pediatric Urology</i> , 2018 , 14, 182.e1-182.e8	1.5	12
70	Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. <i>Journal of Urology</i> , 2021 , 205, 1286-1293	2.5	12
69	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5135-5142	12.9	11
68	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018 , 73, 706-712	10.2	11
67	Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. <i>Journal of Urology</i> , 2020 , 203, 57-61	2.5	11
66	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , 127, 2934-2942	6.4	11
65	Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. <i>BMC Cancer</i> , 2018 , 18, 1296	4.8	11
64	Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 80-87	2.5	11
63	-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3660-3670	2.2	10
62	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2019 , 60, 605	2.9	10
61	Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study. <i>Journal of Urology</i> , 2019 , 201, 886-892	2.5	9
60	The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 166.e17-20	2.8	8
59	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. <i>European Journal of Cancer</i> , 2020 , 126, 21-32	7.5	8
58	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021 , 26, e863-e873	5.7	8
57	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021 , 127, 884-893	6.4	8

56	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5503-5503 ²	7
55	Nonlinear microscopy for detection of prostate cancer: analysis of sensitivity and specificity in radical prostatectomies. <i>Modern Pathology</i> , 2020 , 33, 916-923	9.8 7
54	Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. <i>Journal of Urology</i> , 2021 , 205, 1689-1697	2.5 7
53	Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2021 , 205, 407-413	2.5 7
52	Reducing Pseudoaneurysm and Urine Leak After Robotic Partial Nephrectomy: Results Using the Early Unclamping Technique. <i>Urology</i> , 2019 , 132, 130-135	1.6 6
51	Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 401-10	7.3 6
50	International Robotic Radical Cystectomy Consortium: A way forward. <i>Indian Journal of Urology</i> , 2014 , 30, 314-7	0.8 6
49	Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. <i>Current Urology Reports</i> , 2016 , 17, 4	2.9 5
48	Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. <i>JAMA Oncology</i> , 2018 , 4, 1169-1170	13.4 5
47	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021 , 17, 2923-2939	3.6 5
46	Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1343-1350	13.4 5
45	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , 2019 , 127, 53-60	1.6 4
44	Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. <i>BMC Urology</i> , 2020 , 20, 163	2.2 3
43	Specific targets in sarcoma and developmental therapeutics. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 677-85; quiz 686	7.3 3
42	Continued 5 α -Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. <i>Journal of Urology</i> , 2019 , 201, 106-111 ^{2.5}	2.5 3
41	Delayed Return of Ejaculatory Function in Adolescent Males Treated With Retroperitoneal Lymph Node Dissection and Adjuvant Therapy for Paratesticular Rhabdomyosarcoma. <i>Urology</i> , 2019 , 124, 254-256 ^{1.6}	1.6 3
40	The potential of emerging new therapeutics for the treatment of perivascular epithelioid cell tumors (PEComa). <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 537-543	1.1 3
39	Patient-Reported Quality of Life and Convalescence After Minimally Invasive Kidney Cancer Surgery. <i>Urology</i> , 2020 , 144, 123-129	1.6 2

38	Targeted therapy in sarcoma: should we be lumpers or splitters?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012</i> , 652-7	7.1	2
37	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology, 2018</i> , 36, 79-79	2.2	2
36	Intracorporeal Versus Extracorporeal Neobladder After Robot-assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. <i>Urology, 2021</i> ,	1.6	2
35	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1780-1785	2.3	2
34	Reducing postoperative opioid pill prescribing via a quality improvement approach. <i>International Journal for Quality in Health Care, 2021</i> , 33,	1.9	2
33	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research, 2021</i> , 27, 3861-3866	12.9	2
32	Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. <i>Urology, 2021</i> , 153, 221-227	1.6	2
31	Sterotactic body radiosurgery for primary small renal tumors: A retrospective analysis.. <i>Journal of Clinical Oncology, 2014</i> , 32, 475-475	2.2	1
30	Real-world use of epic for clinical practice (EPIC-CP) to assess patient-reported prostate cancer quality of life in the clinical setting.. <i>Journal of Clinical Oncology, 2015</i> , 33, 18-18	2.2	1
29	Trends in Sales Volumes of Cancer Medicines in Six Asian Countries Working Toward Universal Health Coverage 2018, 4, 220s-220s		1
28	Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance.. <i>Journal of Clinical Oncology, 2018</i> , 36, e17068-e17068	2.2	1
27	The incidence, predictors, and survival of disappearing small renal masses on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations, 2020</i> , 38, 42.e1-42.e6	2.8	1
26	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology, 2020</i> , 9, 1786-1793	2.3	1
25	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. <i>Urologic Oncology: Seminars and Original Investigations, 2021</i> , 39, 785.e1-785.e10	2.8	1
24	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters, 2021</i> , 92, 493-499	4.3	1
23	Perceptions of Oncologists About Sharing Clinic Notes with Patients. <i>Oncologist, 2019</i> , 24, e46-e48	5.7	1
22	Misaligned Incentives in Benign Prostatic Enlargement Surgery: More Complex and Efficacious Procedures Are Earning Fewer Relative Value Units. <i>Journal of Endourology, 2021</i> , 35, 835-839	2.7	1
21	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. <i>Practical Radiation Oncology, 2018</i> , 8, 445-451	2.8	1

20	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1422-1432	4.5	1
19	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2021 ,	6.4	1
18	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
17	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11048-11048	2.2	0
16	Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Endourology</i> , 2021 , 35, 1541-1547	2.7	0
15	Perioperative Aspirin Use is Associated with Bleeding Complications during Robotic Partial Nephrectomy. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002240	2.5	0
14	An Unusual Presentation of Metastatic Urothelial Bladder Carcinoma With Rhabdoid Features Presenting as Obstructive Uropathy. <i>Urology</i> , 2018 , 115, 33-35	1.6	
13	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 733	2.5	
12	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002354	2.5	
11	When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 140-140	2.2	
10	Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 262-262	2.2	
9	Societal costs after renal cancer surgery.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 512-512	2.2	
8	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 22-22	2.2	
7	Cost comparison of robotic, laparoscopic, and open partial nephrectomy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 394-394	2.2	
6	Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 40-40	2.2	
5	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 1293	2.5	
4	Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 927-935	3.8	
3	Pelvic Lymphadenectomy 2018 , 1048-1059		

- | | | |
|---|--|-----|
| 2 | Using Preoperative Pelvic Floor Assessment to Predict Early Return of Continence after Robotic Radical Prostatectomy. <i>Urology</i> , 2021 , 155, 160-164 | 1.6 |
| 1 | The effect of day of discharge on hospital readmission after minimally invasive partial nephrectomy.. <i>Canadian Journal of Urology</i> , 2022 , 29, 11080-11086 | 0.8 |